John A Barrett

Summary

Publications

  1. doi Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution
    John A Barrett
    Research and Development Department, Molecular Insight Pharmaceuticals, Inc, Cambridge, Massachusetts, USA
    Cancer Biother Radiopharm 25:299-308. 2010
  2. pmc Preclinical evaluation of an 131I-labeled benzamide for targeted radiotherapy of metastatic melanoma
    John L Joyal
    Molecular Insight Pharmaceuticals, Cambridge, Massachusetts 02142, USA
    Cancer Res 70:4045-53. 2010
  3. doi Synthesis and evaluation of a series of 99mTc(CO)3+ lisinopril complexes for in vivo imaging of angiotensin-converting enzyme expression
    Frank J Femia
    Molecular Insight Pharmaceuticals Inc, Cambridge, Massachusetts 02142, USA
    J Nucl Med 49:970-7. 2008
  4. pmc Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer
    Shawn M Hillier
    Molecular Insight Pharmaceuticals, Cambridge, Massachusetts, USA
    Cancer Res 69:6932-40. 2009
  5. doi First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer
    John A Barrett
    Molecular Insight Pharmaceuticals, Inc, Cambridge, Massachusetts 02142, USA
    J Nucl Med 54:380-7. 2013

Collaborators

  • Shankar Vallabhajosula
  • R Edward Coleman
  • Vasken Dilsizian
  • Sridhar Nimmagadda
  • John L Joyal
  • Shawn M Hillier
  • John W Babich
  • Kevin P Maresca
  • Frank J Femia
  • Martin G Pomper
  • John C Marquis
  • William C Eckelman
  • Craig N Zimmerman
  • Matthias Friebe
  • James B Stubbs
  • Michael G Stabin
  • Marie Boyd
  • Kenneth Gage
  • Rob Mairs
  • Jianqing Chen
  • James F Kronauge
  • Ludger Dinkelborg
  • Nghi Nguyen
  • Catherine A Foss
  • Omer Aras

Detail Information

Publications5

  1. doi Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution
    John A Barrett
    Research and Development Department, Molecular Insight Pharmaceuticals, Inc, Cambridge, Massachusetts, USA
    Cancer Biother Radiopharm 25:299-308. 2010
    ..Lastly, care must be taken when administering therapeutic doses of the current carrier-added (131)I-MIBG because of its potential to cause adverse cardiovascular side-effects, nausea, and vomiting...
  2. pmc Preclinical evaluation of an 131I-labeled benzamide for targeted radiotherapy of metastatic melanoma
    John L Joyal
    Molecular Insight Pharmaceuticals, Cambridge, Massachusetts 02142, USA
    Cancer Res 70:4045-53. 2010
    ....
  3. doi Synthesis and evaluation of a series of 99mTc(CO)3+ lisinopril complexes for in vivo imaging of angiotensin-converting enzyme expression
    Frank J Femia
    Molecular Insight Pharmaceuticals Inc, Cambridge, Massachusetts 02142, USA
    J Nucl Med 49:970-7. 2008
    ..This agent may be useful in monitoring ACE as a function of disease progression in relevant diseases such as heart failure...
  4. pmc Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer
    Shawn M Hillier
    Molecular Insight Pharmaceuticals, Cambridge, Massachusetts, USA
    Cancer Res 69:6932-40. 2009
    ..PSMA-specific radiopharmaceuticals should provide a novel molecular targeting option for the detection and staging of prostate cancer...
  5. doi First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer
    John A Barrett
    Molecular Insight Pharmaceuticals, Inc, Cambridge, Massachusetts 02142, USA
    J Nucl Med 54:380-7. 2013
    ....